You are here

P&T February 2014

Features

Absence of Onsite Access to Specialty Pharmaceuticals Has Care and Financial Implications
Two competing hospital networks are assembling specialty pharmacy programs to satisfy drug manufacturers’ requirements for delivery of costly, restricted distribution drugs to hospitals. Hospitals’ inability to dispense such drugs can affect patient care and revenue.
Health Care & Law
Legislative and regulatory efforts to address controlled substance diversion and overuse of narcotics are affecting prescription drug utilization and patient care. These initiatives can influence formulary drug selection, prior authorization procedures, and drug utilization strategies.
New and Emerging Treatment Options
A survival benefit has been demonstrated or is under investigation as the primary outcome among certain recently approved agents and investigational agents for men with metastatic castration-resistant prostate cancer that has spread to bone.
Meeting Highlights
55th Annual Meeting and Exposition

Departments

Medication Errors
How to avoid patient harm from a magnesium bolus dose
Prescription: Washington

Hospitals gain a year to meet stage 2 meaningful use rules.

FDA approvals, drug indications, and updates

Simeprevir (Olysio) for chronic hepatitis C infection; coagulation Factor XIII A-subunit (recombinant) (Tretten) for bleeding prevention in congenital Factor XIII A-subunit deficiency; and umeclidinium and vilanterol inhalation powder (Anoro Ellipta) for chronic obstructive pulmonary disease

Drug Forecast

Mipomersen (Kynamro) for homozygous familial hypercholesterolemia